TrialThe New England journal of medicine2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,130 papers cite itlatest 60 shown
this paperpooled ittrialcites it